How deadly is the new coronavirus? Data from the spread of US cases could help answer that.
As new reports of novel coronavirus cases surface along the U.S. West Coast, new research — and the existing disease surveillance network — may finally shed light on some of the most burning questions about the new virus, called SARS-CoV-2.
Among the most pressing questions: How many cases are asymptomatic, versus mild, moderate or severe? And what is the real rate of fatalities compared with the total number of cases?
Initial reports of the new coronavirus emerged from Wuhan, China, in December 2019, with patients presenting with pneumonia of unknown origin. As of March 2, more than 90,000 cases had been confirmed worldwide, including 45,705 cases that ended with patients recovering and more than 3,000 fatalities. On Feb. 28, U.S. health officials confirmed the first known case of the new coronavirus in a patient in the San Francisco Bay Area who had neither traveled abroad nor been exposed to someone known to have traveled to an area affected by the disease (which is called COVID-19). Since then, testing for the new coronavirus has quickly expanded, bringing the known total of cases to 105 in the U.S. Seven people in the U.S. have died from COVID-19.
—Live updates on the coronavirus
—What are the symptoms?
—How does it compare with seasonal flu?
—How does the coronavirus spread?
—Can people spread the coronavirus after they recover?
Tracing U.S. spread
Genetic analysis of the virus circulating on the West Coast suggests that COVID-19 has been transmitting through the region for about six weeks. This community spread was not detected earlier for several reasons. First, about 81% of cases do not require hospitalization, according to data from the outbreak in China. People experiencing symptoms such as a mild fever, cough and congestion are unlikely to visit a doctor. Second, Centers for Disease Control and Prevention (CDC) protocol limited testing to only those with symptoms and a history of travel to an affected region. Finally, there is a lag between virus transmission and fatalities simply because it takes time for the most severe cases to kill. (A World Health Organization report from China found that it took three to six weeks for critical cases to be resolved, either when the patient died or recovered.)
What is not yet clear from the U.S. data is how many people have been infected with the new coronavirus. This number is key for understanding disease severity and the mortality rate — after all, you must know the total number of cases to know what proportion of patients will become severely ill or die. China’s best data so far puts the case-fatality rate at 2.3%. But that number may drop with better detection of mild and asymptomatic cases.
Scientists expect to know more about this number in the coming weeks. Broader testing will help, Paul Biddinger, the vice chairman for emergency preparedness in the emergency medicine department of Massachusetts General Hospital, said in a Harvard T.H. Chan School of Public Health webcast on March 2. However, testing in the next days to weeks will still likely be limited to a subset of the sickest patients, Biddinger said.
“We have, right now, so few tests available that we have to prioritize testing for severe illness,” he said in the webcast.
The weapons of public health
Another method of ferreting out new coronavirus cases is looking at existing influenza and respiratory illness surveillance. This is the bread-and-butter work of public health, said Jennifer Horney, the director of the epidemiology program at the University of Delaware. Most states have what’s called “syndromic surveillance,” in which emergency rooms, emergency medical services, poison control centers and other medical centers report occurrences of influenza-like symptoms. Washington state, for example, uses the Rapid Health Information Network (RHINO) to collect data in near real time.
Most states also have specific flu-monitoring networks, which gather reports of diagnosed influenza cases, usually on a weekly basis. All of this is information that state health departments can use to search for hints of undiagnosed COVID-19.
“They’ll be able to go back and see, Did we have more than a typical number of influenza-like illnesses, given what we know now?” Horney told Live Science.
The number of cases it takes to raise the alarm depends on the infectious agent, the time of year and the population in a region, Horney said. In a large city like Seattle in the middle of winter, it might take hundreds of extra cases to raise the alarm, but in a less populous area in at the end of the season, it could take just a handful.
Already, researchers are seeking out coronavirus cases in a more active way. The Seattle Flu Study, which uses genetic sequencing to track the transmission of seasonal influenza, has begun testing its samples for possible coronavirus as well as flu. The team has already reported finding a case of coronavirus in a Snohomish County high school student who had tested negative for the flu and who had been sent home to recover from mild respiratory symptoms.
Public health researchers will also seek out cases based on interviews, similar to the way epidemiologists track an outbreak of foodborne illness, Horney said. As cases emerge, researchers reach out to hospitals and clinics in the affected area, searching for patients with telltale symptoms who were not diagnosed at the time of treatment. They can then interview those people to find out everywhere they’ve been and everyone they’ve interacted with. In the case of salmonella, a pattern might pop out: Everyone’s eaten the same bagged spinach, or the same brand of fruit cup. In the case of COVID-19, the researchers might find that people with symptoms frequented the same stores or worked in the same office park. Already, the Washington state health department has monitoring contacts of the people already confirmed to have the coronavirus.
“If we find that shared exposure, then we can link all those cases, regardless of severity,” Horney said.
Pyramid of cases
Tracking people with symptoms — whether mild, moderate or severe — is only the beginning, however. One big question about the new coronavirus is how many people transmit COVID-19 without showing symptoms at all, or showing so few symptoms they hardly realize they are sick, Marc Lipsitch, an epidemiologist at the Harvard T.H. Chan School of Public Health, said in the March 2 webcast. Asymptomatic carriers and people with mild symptoms may be like the base of the iceberg, Lipsitch said. They’re hard to detect, but they’re very important for modeling how the disease will spread.
“When we model transmission and when we project how many people are going to get infected, the models don’t know how many people are ‘sick’ or ‘really sick,’ they know how many are infected” regardless of severity, Lipsitch said.
Scientists in China have already started doing studies that look for antibodies to the virus in people’s blood, Lipsitch said. These studies are the only surefire way to confirm that someone has been infected with SARS-CoV-2 after the person recovers. The research will take time, but the more researchers know about the speed of the disease’s spread, the more they’ll be able to say about the likely length of the outbreak.
“What ultimately brings an epidemic under control,” Lipsitch said, “is most people in the population becoming immune.”
- The 9 Deadliest Viruses on Earth
- 27 Devastating Infectious Diseases
- 11 Surprising Facts About the Respiratory System
Originally published on Live Science.
OFFER: Save at least 53% with our latest magazine deal!
With impressive cutaway illustrations that show how things function, and mindblowing photography of the world’s most inspiring spectacles, How It Works represents the pinnacle of engaging, factual fun for a mainstream audience keen to keep up with the latest tech and the most impressive phenomena on the planet and beyond. Written and presented in a style that makes even the most complex subjects interesting and easy to understand, How It Works is enjoyed by readers of all ages.
View Deal
Source: Read Full Article